Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes
    Meeting Abstract

    Voon, P. J.; Riely, G. J.; Lepisto, E. M.; Lavery, J. A.; Warner, J. L.; LeNoue-Newton, M. L.; Sweeney, S. M.; McCarthy, C. G.; Samantha, B.; Panageas, K. S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
    Meeting Abstract

    Yu, H. A.; Ambrose, H.; Baik, C.; Cho, B. C.; Cocco, E.; Goldberg, S. B.; Goldman, J. W.; Kraljevic, S.; de Langen, A. J.; Okamoto, I.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Garassino, M. C. C.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F. F.; Mazieres, J.; Cortot, A. B.; Raskin, J.; Thomas, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
    Meeting Abstract

    Yang, J. C. H.; Ramalingam, S. S.; Kim, T. M.; Kim, S. W.; Riely, G. J.; Mekhail, T.; Nguyen, D.; Garcia Campelo, M. R.; Felip, E.; Bazhenova, L.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
    Meeting Abstract

    Margolin, K. A.; Korn, R.; Farwell, M.; Postow, M. A.; Hays, D.; Wilson, I. A.; Le, W. H.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
    Meeting Abstract

    Ruszniewski, P. B.; Caplin, M. E.; Kunz, P. L.; Bodei, L.; Hendifar, A. E.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; Grande, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
    Meeting Abstract

    Nguyen, D.; Ramalingam, S. S.; Spira, A.; Riely, G. J.; Kim, T. M.; Yang, J. C. H.; Piotrowska, Z.; Garcia Campelo, M. R.; Felip, E.; Bazhenova, L.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
    Meeting Abstract

    Janku, F.; Bauer, S.; Shoumariyeh, K.; Jones, R. L.; Spreafico, A.; Jennings, J.; Psoinos, C.; Meade, J.; Ruiz-Soto, R.; Chi, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
    Meeting Abstract

    Baudin, E.; Horsch, D.; Singh, S.; Caplin, M. E.; Ferone, D.; Wolin, E. M.; Capdevila, J.; Buikhuisen, W. A.; Raderer, M.; Dansin, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A. N.; Olszanski, A. J.; Nyakas, M.; Hornyak, T. J.; Wolchok, J. D.; Levitsky, V.; Møller, A. S.; Kuryk, L.; Handeland, K. R.; Jäderberg, M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save